Granules India Ltd
About
Granules India is committed to producing safe, affordable, and efficient pharmaceutical products in the Indian market. One of its manufacturing plants is also located in Virginia in the US, while the other six plants are in Hyderabad and Visakhapatnam in India. Its product portfolio includes active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates (PFIs), and finished dosages. Among the APIs, its paracetamol, metformin, guaifenesin, and methocarbamol are the most widely recognised. Within the finished dosages, Granules offers tablets, press fits, capsules, suspensions, oral solutions, and powders for oral solutions. With 87 regulatory approvals for its 60+ products, the company was able to generate a revenue of 4506 cr in FY24.
Featured In Fortune India Ranking
Financial Data 2024
Fortune India Coverage
Financial Data
| PARAMETERS | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (INR Cr) | 4698 2.8% | 4571 16.2% | 3935 13.6% | 3463 27.2% | 2722 11.7% | 2438 41.9% | 1718 18.9% | 1446 3.3% | 1399 6.0% | 1320 17.2% | 1126 44.9% | 777 17.6% | 661 38.4% | 478 1.5% | 471 63.4% | 288 5.7% | 273 - |
| Net Operating Income (INR Cr) | 4506 -0.12% | 4512 19.84% | 3765 16.29% | 3238 24.59% | 2599 14.02% | 2279 35.29% | 1685 19.43% | 1411 3.93% | 1357 4.91% | 1294 18.05% | 1096 43.37% | 764 16.88% | 654 37.62% | 475 3.13% | 461 59.52% | 289 12.78% | 256 36.13% |
| Profit (INR Cr) | 405 -21.5% | 517 25.2% | 413 -24.9% | 549 63.8% | 335 41.9% | 236 78.3% | 133 -19.4% | 165 33.8% | 123 35.3% | 91 20.8% | 75 131.0% | 33 8.8% | 30 43.3% | 21 -31.2% | 30 614.6% | 4 -52.8% | 9 - |
| Assets (INR Cr) | 4579 14.5% | 4000 7.5% | 3722 22.1% | 3047 10.5% | 2757 8.9% | 2533 10.6% | 2290 46.1% | 1567 19.8% | 1309 42.6% | 917 14.4% | 802 46.5% | 547 21.6% | 450 31.7% | 342 -2.0% | 349 -2.6% | 358 12.6% | 318 - |
| Net Worth (INR Cr) | 3226 13.8% | 2835 9.6% | 2587 19.0% | 2173 17.9% | 1844 20.6% | 1529 17.3% | 1304 44.3% | 904 36.6% | 662 53.4% | 431 21.1% | 356 29.5% | 275 12.2% | 245 11.5% | 220 8.6% | 202 15.7% | 175 0.8% | 174 3.7% |
| Employee Cost (INR Cr) | 550 30.9% | 420 14.7% | 366 13.0% | 324 25.2% | 259 23.5% | 210 27.0% | 165 17.9% | 140 19.2% | 118 9.9% | 107 24.6% | 86 43.8% | 60 31.4% | 45 36.2% | 33 19.6% | 28 58.9% | 18 1.7% | 17 - |
| Interest Cost (INR Cr) | 106 | 56 | 23 | 26 | 27 | 28 | 33 | 32 | 37 | 32 | 20 | 18 | 17 | 12 | 18 | 16 | 13 |
| Cash & Bank Balance (INR Cr) | 386 | 313 | 409 | 271 | 284 | 89 | 116 | 50 | 130 | 65 | 42 | 42 | 32 | 12 | 13 | 13 | 11 |
| Total Debt (INR Cr) | 1315 | 1136 | 1106 | 849 | 892 | 991 | 978 | 657 | 641 | 482 | 442 | 270 | 204 | 121 | 147 | 183 | 145 |
Key Financial Ratios
| PARAMETERS | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Profit As % Of Revenues | 8.6% | 11.3% | 10.5% | 15.9% | 12.3% | 9.7% | 7.7% | 11.4% | 8.8% | 6.9% | 6.7% | 4.2% | 4.5% | 4.4% | 6.5% | 1.5% | 3.3% |
| Profit As % Of Assets | 8.9% | 12.9% | 11.1% | 18.0% | 12.2% | 9.3% | 5.8% | 10.5% | 9.4% | 9.9% | 9.4% | 6.0% | 6.7% | 6.1% | 8.7% | 1.2% | 2.8% |
| Profit As % Of Networth | 12.6% | 18.2% | 16.0% | 25.3% | 18.2% | 15.5% | 10.2% | 18.2% | 18.6% | 21.1% | 21.1% | 11.9% | 12.2% | 9.5% | 15.0% | 2.4% | 5.2% |
| Interest Cost to EBITDA % | 12.4% | 6.1% | 3.2% | 3.1% | 5.1% | 7.4% | 11.9% | 10.8% | 13.4% | 15.5% | 12.9% | 20.8% | 21.4% | 21.3% | 28.7% | 47.4% | 36.5% |
| Debt to Equity Ratio | 0.41 | 0.40 | 0.43 | 0.39 | 0.48 | 0.65 | 0.75 | 0.73 | 0.97 | 1.12 | 1.24 | 0.98 | 0.83 | 0.55 | 0.72 | 1.05 | 0.83 |
| RONW | 13.4% | 19.1% | 17.3% | 27.4% | 19.9% | 16.7% | 12.0% | 21.0% | 22.9% | 23.1% | 23.9% | 12.5% | 12.9% | 9.9% | 16.1% | 3.3% | 5.3% |
| ROCE | 15.2% | 19.3% | 17.2% | 25.2% | 18.1% | 14.7% | 11.9% | 18.2% | 20.1% | 18.7% | 19.7% | 12.8% | 15.1% | 11.2% | 15.7% | 9.0% | 8.3% |